Scarica l'app Stockscreener
102.87
0.48%
0.49
Dopo l'orario di chiusura:
102.90
0.03
+0.03%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$102.38
Aprire:
$102.02
Volume 24 ore:
5.43M
Relative Volume:
0.50
Capitalizzazione di mercato:
$178.75B
Reddito:
$44.33B
Utile/perdita netta:
$6.50B
Rapporto P/E:
27.68
EPS:
3.717
Flusso di cassa netto:
$7.40B
1 W Prestazione:
-1.63%
1M Prestazione:
-9.86%
6M Prestazione:
-22.65%
1 anno Prestazione:
-22.03%
Intervallo 1D:
$101.55
$103.47
Intervallo di 1 settimana:
$100.88
$105.46
Portata 52W:
$100.88
$139.06
Abbott Laboratories Stock (ABT) Company Profile
Nome
Abbott Laboratories
Settore
Industria
Telefono
(224) 667-6100
Indirizzo
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
102.87 | 178.75B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
331.54 | 126.97B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.63 | 111.22B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.82 | 93.36B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
81.05 | 46.73B | 6.07B | 1.06B | 1.34B | 1.8063 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-10 | Iniziato | The Benchmark Company | Buy |
| 2025-07-18 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-06-16 | Iniziato | Leerink Partners | Market Perform |
| 2024-10-08 | Iniziato | Oppenheimer | Outperform |
| 2024-09-19 | Iniziato | Piper Sandler | Overweight |
| 2024-07-30 | Downgrade | Edward Jones | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2023-07-21 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Reiterato | Barclays | Overweight |
| 2023-04-20 | Reiterato | Bernstein | Outperform |
| 2023-04-20 | Reiterato | JP Morgan | Overweight |
| 2023-04-20 | Reiterato | Raymond James | Outperform |
| 2023-04-20 | Reiterato | UBS | Buy |
| 2023-04-20 | Reiterato | Wolfe Research | Underperform |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2022-10-26 | Iniziato | Mizuho | Neutral |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-07-06 | Iniziato | Wolfe Research | Underperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-01-27 | Reiterato | Credit Suisse | Outperform |
| 2022-01-27 | Reiterato | Morgan Stanley | Overweight |
| 2022-01-27 | Reiterato | Raymond James | Outperform |
| 2022-01-27 | Reiterato | UBS | Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-10-27 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Iniziato | Redburn | Neutral |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Neutral |
| 2021-01-28 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Outperform |
| 2020-06-01 | Downgrade | Goldman | Neutral → Sell |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Neutral |
| 2020-02-06 | Ripresa | BTIG Research | Neutral |
| 2020-01-02 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-06-13 | Reiterato | BofA/Merrill | Buy |
| 2019-02-07 | Reiterato | BofA/Merrill | Buy |
| 2019-01-02 | Downgrade | Citigroup | Neutral → Sell |
| 2018-11-30 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-10-16 | Iniziato | Barclays | Overweight |
| 2018-06-27 | Iniziato | Bernstein | Outperform |
| 2018-01-30 | Reiterato | Citigroup | Neutral |
| 2018-01-25 | Reiterato | Stifel | Buy |
| 2018-01-25 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Iniziato | Evercore ISI | Outperform |
| 2018-01-02 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-10-19 | Reiterato | Stifel | Buy |
Mostra tutto
Abbott Laboratories Borsa (ABT) Ultime notizie
The Best Dividend ETF to Buy in April 2026 If You Want Passive Income - The Motley Fool
Abbott Laboratories Embarks on a Transformative $23 Billion Acquisition - AD HOC NEWS
ABT SEC FilingsAbbott Labs 10-K, 10-Q, 8-K Forms - Stock Titan
Abbott launches nationwide campaign on National Vitamin C Day to highlight role of micronutrient in wellness - MediaNews4U
A Dividend Dynasty: Abbott Laboratories' Enduring Payout Streak - AD HOC NEWS
Exact Sciences Corp. stock: Acquired by Abbott – What it means for you now - AD HOC NEWS
Erste Group Keeps Their Hold Rating on Abbott Laboratories (ABT) - The Globe and Mail
Abbott Stock Sits 26% Off Its Peak While Analysts Back a $132 Mean Price Target - TIKR.com
Abbott Laboratories (ABT) latest stock news and headlines - Yahoo Finance Singapore
Analysts’ Top Healthcare Picks: Abbott Laboratories (ABT), Cogent Biosciences (COGT) - The Globe and Mail
Aberdeen Group plc Increases Holdings in Abbott Laboratories $ABT - MarketBeat
Abbott India Ltd Stock: A Stable Player in India's Booming Healthcare Sector for Long-Term Investors - AD HOC NEWS
What Abbott Laboratories (ABT)'s Oncology Test Integration Into OncoEMR Means For Shareholders - simplywall.st
Abbott Laboratories (ABT) director receives 382 stock equivalent units as fees - Stock Titan
Director at Abbott (NYSE: ABT) receives stock equivalent unit award - Stock Titan
Abbott (ABT) director Gonzalez receives 321 stock equivalent units as fees - Stock Titan
Abbott (ABT) director Robert Alpern awarded 76 stock equivalent units as fees - Stock Titan
Abbott Laboratories (ABT) director Nita Ahuja granted 102 stock equivalent units - Stock Titan
Sinocare Can't Scrap Abbott's Glucose Monitor Ban At UPC - Law360
Compagnie Lombard Odier SCmA Makes New Investment in Abbott Laboratories $ABT - MarketBeat
Abbott India Ltd Stock: Steady Growth in India's Pharmaceutical Sector Amid Evolving Healthcare Dema - AD HOC NEWS
Bank Pictet & Cie Europe AG Decreases Position in Abbott Laboratories $ABT - MarketBeat
Banque Pictet & Cie SA Sells 83,130 Shares of Abbott Laboratories $ABT - MarketBeat
Drug Delivery Device Market Is Booming Worldwide 2026-2033 | - openPR.com
Abbott Laboratories Expands into Wearable Technology Through Whoop Investment - AD HOC NEWS
Abbott’s Whoop Investment Puts Digital Health Wearables On Shareholders’ Radar - finance.yahoo.com
Assessing Abbott Laboratories (ABT) Valuation After New Flatiron Health Oncology Integration - simplywall.st
Abbott Laboratories completed the acquisition of North Island Assets of Synlait Milk from Synlait Milk Limited. - MarketScreener
Abbott joins $575M funding round for wearable maker Whoop - MassDevice
Abbott: A Brighter Investment Case Heading Into Q1 Earnings (Rating Upgrade) (NYSE:ABT) - Seeking Alpha
Reasons to Retain Abbott Stock in Your Portfolio Now - TradingView
Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock - finance.yahoo.com
20,751 Shares in Abbott Laboratories $ABT Bought by Shrier Wealth Management LLC - MarketBeat
Abbott Laboratories Pakistan : Change in Date and Time of the 77th Annual General Meeting - MarketScreener
List of 29 Acquisitions by Abbott (Apr 2026) - Tracxn
Whoop raises $575M—Abbott, LeBron James, Cristiano Ronaldo among the investors - Cardiovascular Business
Abbott Oncology Integration Into OncoEMR Tests Long Term Growth Story - simplywall.st
Whoop raises $575M, adds Abbott as strategic investor - medtechdive.com
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Abbott Laboratories (ABT) - The Globe and Mail
Abbott integrates Precision Oncology portfolio into Flatiron’s OncoEMR - Yahoo Finance
BTIG Research Lowers Abbott Laboratories (NYSE:ABT) Price Target to $131.00 - MarketBeat
BTIG Research Adjusts Abbott Laboratories PT to $131 From $140, Maintains Buy Rating - MarketScreener
Whoop Raises $575M at $10.1B Valuation, Abbott Joins as Investor - Athletech News
Abbott Laboratories $ABT Position Trimmed by J. Safra Sarasin Holding AG - MarketBeat
Abbott Laboratories $ABT Shares Bought by Mn Services Vermogensbeheer B.V. - MarketBeat
Abbott (ABT) Enhances Cancer Care with OncoEMR Test Integration - GuruFocus
Abbott (ABT) Dips More Than Broader Market: What You Should Know - Yahoo Finance Australia
Dairy industry consolidation | Lactalis, Abbott Complete Major NZ Dairy Deals - en.edairynews.com
SCHD ETF Rebalance Adds Abbott, UnitedHealth as Dividend Fund Inflows Hit 4-Year High - TechStock²
Abbott Laboratories stock underperforms Monday when compared to competitors - MarketWatch
Abbott Laboratories (NYSE:ABT) Reaches New 1-Year LowShould You Sell? - MarketBeat
Abbott Laboratories Azioni (ABT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.65%
0.26%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):